Protalix

Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment

CARMIEL, Israel, Sept. 28 /PRNewswire-FirstCall/ -- The Russell Investment Group has advised Protalix Biotherapeutics (Amex: PLX ) that there will be a float weight adjustment effective after the close of trading on September 28, 2007 in the following indexes: Russell 2000, Russell 2000 Growt...

Protalix BioTherapeutics Appoints Professor Roger D. Kornberg to Board of Directors

...explore new biotherapeutic opportunities." About protalix BioTherapeutics, Inc. protalix is a biopharmaceutical company. Its goal is to bec...od for the expression of recombinant proteins that protalix believes is safe and scalable and will allow for t...

Protalix BioTherapeutics Announces Resignation of Board Members

...ation committee of the Board of Directors. About protalix BioTherapeutics, Inc. protalix is a biopharmaceutical company. Its goal is to bec...od for the expression of recombinant proteins that protalix believes is safe and scalable and will allow for t...

Protalix BioTherapeutics' prGCD Named One of the Five Most Promising Drugs Entering Phase III Trials by Thomson Scientific

... a treatment for Gaucher disease patients. About protalix BioTherapeutics, Inc. protalix is a biopharmaceutical company. Its goal is to bec...od for the expression of recombinant proteins that protalix believes is safe and scalable and will allow for t...

Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline

...e Most Promising Drugs Entering Phase III Trials * bevasiranib sodium, (Wet AMD), Opko * recombinant active glucocerebrosidase, (Gaucher's disease), protalix * odanacatib, (osteoporosis), Merck & Co * laquinimod, (multiple sclerosis), Active Biotech/Teva * elesclomol, (solid tumors), Synta The Five Mos...

Protalix in Medical Technology

Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study

...ning. Based on these positive preliminary results, protalix has extended its agreement with Yissum to include ... look forward to continuing the collaboration with protalix toward commercializing the discoveries made by Pro...ging relief to patients around the world." About protalix BioTherapeutics, Inc. ...

Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD

...of prGCD in this phase III clinical trial." About protalix BioTherapeutics, Inc. protalix is a clinical stage biopharmaceutical company. Its...od for the expression of recombinant proteins that protalix believes is safe and scalable and will allow for t...

Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD

...he medical experts and patient community." About protalix BioTherapeutics, Inc. Protalix's proprietary tec...rial production of recombinant biopharmaceuticals. protalix is pursuing advanced clinical studies for its enzy...information, except as required by law. CONTACT: protalix Investor Relations: ,+972-4-988-9488; AMEX IR Alli...

Protalix in Biological Technology

Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel

...t candidates in our development pipeline." About protalix BioTherapeutics, Inc. protalix is a biopharmaceutical company. Its goal is to bec...od for the expression of recombinant proteins that protalix believes is safe and scalable and will allow for t...

Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders

...other filings by the Company with the SEC. About protalix BioTherapeutics, Inc. protalix is a biopharmaceutical company. Its goal is to bec...od for the expression of recombinant proteins that protalix believes is safe and scalable and will allow for t...

Protalix BioTherapeutics to Present at CIBC World Markets 18th Annual Healthcare Conference

...a period of 90 days after the presentation. About protalix BioTherapeutics, Inc. protalix is a biopharmaceutical company. Its goal is to bec...od for the expression of recombinant proteins that protalix believes is safe and scalable and will allow for t...

Protalix BioTherapeutics Announces Pricing of Public Offering of Common Stock

...e securities laws of any such jurisdiction. About protalix BioTherapeutics, Inc. protalix is a biopharmaceutical company. Its goal is to bec...od for the expression of recombinant proteins that protalix believes is safe and scalable and will allow for t...

Protalix BioTherapeutics Announces Public Offering of Common Stock

...any's common stock on the American Stock Exchange. protalix BioTherapeutics will not receive any proceeds from... York, NY 10171, Toll Free: (888) 827-7275. About protalix BioTherapeutics, Inc. protalix is a biopharmaceutical company. Its goal is to bec...

Protalix BioTherapeutics to Present at UBS Global Life Sciences Conference

... will be available for a period of 30 days. About protalix BioTherapeutics, Inc. protalix is a clinical stage biopharmaceutical company. Its...clinical trial is based on an agreement reached by protalix with the United States Food and Drug Administratio...